Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Italy
  4. Borsa Italiana
  5. DiaSorin S.p.A.
  6. Summary
    DIA   IT0003492391

DIASORIN S.P.A.

(DIA)
  Report
Delayed Borsa Italiana  -  11:40 2022-09-27 am EDT
115.60 EUR   -0.73%
09/14Italy's DiaSorin Gets US FDA Nod For Simplexa COVID-19 Direct Testing Kit
MT
09/13Diasorin S P A : Roadshows Presentation -Settembre 2022
PU
08/09DiaSorin S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Borsa Italiana
09/21/2022 09/22/2022 09/23/2022 09/26/2022 09/27/2022 Date
127.5(c) 119.15(c) 115.4(c) 116.45(c) 115.6 Last
89 329 200 313 115 802 103 150 72 363 Volume
+2.00% -6.55% -3.15% +0.91% -0.73% Change
More quotes
Estimated financial data (e)
Sales 2022 1 328 M 1 281 M 1 281 M
Net income 2022 258 M 248 M 248 M
Net Debt 2022 859 M 829 M 829 M
P/E ratio 2022 24,9x
Yield 2022 0,96%
Sales 2023 1 358 M 1 310 M 1 310 M
Net income 2023 265 M 256 M 256 M
Net Debt 2023 645 M 622 M 622 M
P/E ratio 2023 24,5x
Yield 2023 0,99%
Capitalization 6 215 M 5 996 M 5 996 M
EV / Sales 2022 5,33x
EV / Sales 2023 5,05x
Nbr of Employees 3 350
Free-Float 39,3%
More Financials
Company
DiaSorin S.p.A. specializes in the development, manufacturing and marketing of in vitro diagnostic reagents. The products are used in treating infectious and viral diseases, thyroid pathologies, cancer, etc. At the end of 2021, the group had 10 production sites located in Italy, the United States (6), Canada, Germany, and the United Kingdom. Net sales are distributed geographically as follows: Europe and Africa... 
More about the company
Ratings of DiaSorin S.p.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about DIASORIN S.P.A.
09/14Italy's DiaSorin Gets US FDA Nod For Simplexa COVID-19 Direct Testing Kit
MT
09/13Diasorin S P A : Roadshows Presentation -Settembre 2022
PU
08/09DiaSorin S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/09Diasorin S P A : Half-Year Financial Report at June 30, 2022
PU
08/03Transcript : DiaSorin S.p.A., H1 2022 Earnings Call, Aug 03, 2022
CI
08/03DiaSorin Boosts FY22 Guidance on Increased COVID-19 Test Sales
MT
08/03Diasorin S P A : Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidanc..
PU
08/03Diasorin S P A : risultati H1 2022
PU
08/03Tranche Update on DiaSorin S.p.A.'s Equity Buyback Plan announced on May 30, 2022.
CI
08/03DIASORIN S.P.A. : Half-year results
CO
08/03DIASORIN S.P.A. : Press Release
CO
07/14Diasorin S P A : receives FDA 510(k) clearance for its LIAISON« MeMed BV« test
PU
06/07Diasorin S P A : Execution of the project for the redefinition of the corporate structure ..
PU
06/01Diasorin S P A : Consolidated non-financial disclosure 2021, excerpt from the annual finan..
PU
05/30DiaSorin S.p.A. announces an Equity Buyback for 1,500,000 shares, representing 2.68% of..
CI
More news
News in other languages on DIASORIN S.P.A.
09/22BORSA: passa in positivo con banche, Unicredit in rally
09/22BORSA: partenza in rosso in Ue, Tim in controtendenza
09/21BORSA: commento di chiusura
09/20Borsa Milano, in calo dopo intervento Svezia su tassi, giù banche e risparmio gestito
09/20Borsa Milano, azzera rialzo iniziale, bene banche e lusso, pesante Mps
More news
ETFs positioned on DIASORIN S.P.A.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
VanEck Global Healthcare Leaders ETF - AUD1.97%-4.04%-NC
L&G Healthcare Breakthrough - Acc - USD1.54%-8.73%-World
Robo Global Healthcare Technology and Innov...1.5%-8.39%World
ALPS Disruptive Technologies ETF - USD1.08%-6.60%World
Franklin FTSE Italy ETF - USD0.98%-7.82%Italy
More ETFs positioned on DIASORIN S.P.A.
Chart DIASORIN S.P.A.
Duration : Period :
DiaSorin S.p.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DIASORIN S.P.A.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 116,45 €
Average target price 150,97 €
Spread / Average Target 29,6%
EPS Revisions
Managers and Directors
Carlo Rosa Chief Executive Officer, Executive Director & GM
Piergiorgio Pedron Deputy Chief Financial Officer
Michele Denegri Chairman
Franco Moscetti Independent Director
Roberta Somati Independent Director
Sector and Competitors
1st jan.Capi. (M$)
DIASORIN S.P.A.-31.08%5 996
BIOMÉRIEUX-33.82%9 486
LANTHEUS HOLDINGS, INC.136.62%4 699
NATERA, INC.-53.27%4 231
AUTOBIO DIAGNOSTICS CO., LTD.-12.79%3 974
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.-22.81%3 786